Literature DB >> 15781029

Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration.

Ivor L Gerber1, Malcolm E Legget, Teena M West, A Mark Richards, Ralph A H Stewart.   

Abstract

In 29 initially asymptomatic patients with aortic stenosis followed for an average of 18 months, patients with a N-terminal pro-brain natriuretic peptide (NT-pro-BNP) level above the normal range at baseline were more likely to develop symptoms during follow-up compared with patients with NT-pro-BNP within normal limits. The average increase in NT-pro-BNP per year was greater for patients who developed symptoms compared with patients who remained asymptomatic. Aortic valve area, peak aortic velocity, and the ejection fraction were less reliable predictors of symptom onset. Measurement of NT-pro-BNP in addition to clinical assessment and echocardiography may allow more reliable follow-up and timing of valve replacement for aortic stenosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781029     DOI: 10.1016/j.amjcard.2004.11.053

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

Review 1.  Evaluation of aortic stenosis: an update--including low-flow States, myocardial mechanics, and stress testing.

Authors:  Luc A Pierard; Raluca Dulgheru
Journal:  Curr Cardiol Rep       Date:  2015-06       Impact factor: 2.931

Review 2.  Biomarkers of Calcific Aortic Valve Disease.

Authors:  Aeron Small; Daniel Kiss; Jay Giri; Saif Anwaruddin; Hasan Siddiqi; Marie Guerraty; Julio A Chirinos; Giovanni Ferrari; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-02-02       Impact factor: 8.311

Review 3.  Natriuretic peptides in heart valve disease.

Authors:  S G Ray
Journal:  Heart       Date:  2005-10-26       Impact factor: 5.994

4.  Utility of NT-pro-BNP in patients undergoing transapical aortic valve replacement.

Authors:  Roman Pfister; Thorsten Wahlers; Frank M Baer; Max Scherner; Justus Strauch; Erland Erdmann
Journal:  Clin Res Cardiol       Date:  2010-02-06       Impact factor: 5.460

5.  Copeptin constitutes a novel biomarker of degenerative aortic stenosis.

Authors:  Katarzyna Mizia-Stec; Bartosz Lasota; Magdalena Mizia; Artur Chmiel; Tomasz Adamczyk; Jerzy Chudek; Zbigniew Gasior
Journal:  Heart Vessels       Date:  2012-11-10       Impact factor: 2.037

Review 6.  Natriuretic peptides in the management of aortic stenosis.

Authors:  Jutta Bergler-Klein
Journal:  Curr Cardiol Rep       Date:  2009-03       Impact factor: 2.931

7.  Natriuretic Peptides and Assessment of Cardiovascular Disease Risk in Asymptomatic Persons.

Authors:  Lori B Daniels
Journal:  Curr Cardiovasc Risk Rep       Date:  2010-02-17

8.  Usefulness of exercise-stress echocardiography for risk stratification of true asymptomatic patients with aortic valve stenosis.

Authors:  Sylvestre Maréchaux; Zeineb Hachicha; Annaïk Bellouin; Jean G Dumesnil; Patrick Meimoun; Agnès Pasquet; Sébastien Bergeron; Marie Arsenault; Thierry Le Tourneau; Pierre Vladimir Ennezat; Philippe Pibarot
Journal:  Eur Heart J       Date:  2010-03-21       Impact factor: 29.983

9.  The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology.

Authors:  Van Kimmenade
Journal:  Biomark Insights       Date:  2007-02-07

10.  Management of asymptomatic severe aortic stenosis.

Authors:  Robert L Stewart; Kwan L Chan
Journal:  Curr Cardiol Rev       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.